Analysis of cytokine production patterns of peripheral blood mononuclear cells from a rheumatoid arthritis patient successfully treated with rituximab

Modern Rheumatology

Volumn 20, Issue 2, 2010, Pages 183-187

  Yamamoto, Akinori ^a   Sato, Kojiro ^a   Miyoshi, Fumihiko ^a   Shindo, Yasufumi ^a   Yoshida, Yoshihiro ^a   Yokota, Kazuhiro ^a   Nakajima, Kyoichi ^a   Akiba, Haruhiko ^a   Asanuma, Yu ^a   Akiyama, Yuji ^a   Mimura, Toshihide ^a  

^a SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Rheumatoid arthritis; Rituximab; Th1; Th17; Th2

Indexed keywords

ADALIMUMAB; BETAMETHASONE; BUCILLAMINE; C REACTIVE PROTEIN; CHLORPHENIRAMINE MALEATE; DEXAMETHASONE 21 PALMITATE; DEXAMETHASONE DERIVATIVE; DEXAMETHASONE SODIUM PHOSPHATE; ETANERCEPT; GAMMA INTERFERON; HYDROCORTISONE SODIUM SUCCINATE; IBUPROFEN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 4; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; STROMELYSIN; TACROLIMUS; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLUSHING; HERPES ZOSTER; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; PANNICULITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TH1 CELL; TH17 CELL; TH2 CELL;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CD4-CD8 RATIO; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE SUBSETS; MIDDLE AGED;

EID: 77954756885     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0244-3     Document Type: Article

References (15)

1. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-10.
2. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-7.
3. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761-9.
4. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987-97.
5. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865-76.
6. Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:2652-61.
7. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-81. (Pubitemid 38758544)
8. Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56:1417-23.
9. Sato K. Th17 cells and rheumatoid arthritis-from the standpoint of osteoclast differentiation. Allergol Int. 2008;57:109-14.
10. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821-52.
11. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602.
12. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48:2146-54.
13. Harris J, Vaughan JH. Transfusion studies in rheumatoid arthritis. Arthritis Rheum. 1961;4:47-55.
14. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806.
15. Manzo A, Pitzalis C. Lymphoid tissue reactions in rheumatoid arthritis. Autoimmun Rev. 2007;7:30-4.